[Results of a clinical study of carminomycin in primary disseminated forms, recurrences and metastases of breast cancer].
A more than 50% regression of tumor was observed in 19% of 64 patients treated with carminomycin for advanced primary breast cancer, its recurrences and metastases. A clinically-significant effect of treatment was recorded in 42%, while tumor process was arrested for at least 3-4 months in 37% of cases. The index of more than 50% regression of tumor rose to 28% in a group of 27 patients, following repeated courses of the drug. Only a slight toxic side--effect was observed, repeated courses included. Moderate leukopenia and a slight cardiotoxic effect were registered in 17%; phlebitis--in 12%. Carminomycin treatment should be recommended for advanced primary breast cancer, its recurrences an metastases, when other chemotherapeutic means fail to stop tumor process.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D002360:Carubicin / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D013997:Time Factors
D002360:Carubicin; D003630:Daunorubicin
Rezul'taty klinicheskogo izucheniia karminomitsina pri pervichno-rasprostranennykh formakh, retsidivakh i metastazakh raka molochnoĭ zhelezy.